Clarix is a noninvasive prenatal test (NIPT) that allows our experts to evaluate the genetic health of your baby or babies.
This NIPT genetic testing technique is done by analyzing small amounts of fetal DNA found in the mother’s blood. It’s a safe and reliable way to detect certain genetic conditions, such as Down syndrome and other chromosomal abnormalities, without the risks associated with invasive procedures.
Additionally, this prenatal DNA test can determine the baby’s gender as early as 10 weeks into the pregnancy. At our prenatal testing center, we use the latest technology to ensure accurate results.
If you have questions about Clarix or are considering choosing this test to ease your mind and gain full confidence about you and your baby’s health, reach out to your Maternal-Fetal expert, and they’ll guide you through this process.
Ask the Maternal-Fetal specialist leading your case if this is the right option for you, and he or she will point you in the right direction.
Other available tests on the market have proven to be unsafe and less effective, given the fact that they fail to analyze each chromosome while also being invasive.
Chromosomes are structures that carry our DNA. In humans, each cell contains 23 pairs of chromosomes, for a total of 46. Of these chromosomes, 23 come from the mother and 23 from the father.
Nowadays, there are several types of prenatal tests, which are classified according to the method of obtaining the sample and the type of analysis that is carried out.
Depending on the method used to obtain the sample, we can find invasive methods such as amniocentesis, cordocentesis, and chorionic villus sampling, which may pose a risk to achieving a full-term pregnancy (with a 5% risk of miscarriage).
However, at Ingenes, we opt for noninvasive methods, such as Clarix, which pose no risk for the mother or the future child or children, as the sample is sourced from fetal cell-free DNA found in the mother’s bloodstream.
Women who become pregnant over the age of 40 carry the greatest chance of having a baby with a chromosomal abnormality.
This graph shows the estimated risk of having a baby with Down Syndrome in relation to the mother’s age.
This screening test is ideal for expectant mothers who have become pregnant spontaneously or through Assisted Reproductive Technology Treatments.
Expectant mothers with advanced maternal age may be prone to developing chromosomal abnormalities (women over 35 years of age).
Expectant mothers who wish to discover their baby’s gender as early as the 10th gestational week.
Patients who have undergone an Assisted Reproduction Treatment without the screening of a Preimplantation Genetic Testing for aneuploidies (PGT-A). At Ingenes, the Clarix test can be used with singleton and twin pregnancies.
This test can serve as a complement to ultrasound and standard fetal risk screening carried out during the first trimester.
The main benefit is the early detection of the most critical chromosomal abnormalities, this allows us to provide you with any necessary guidance, and obtaining this information at the right time is key in the decision-making process to guarantee you and your baby’s well-being.
Gender determination: A baby’s gender may be determined by ultrasound, a specialized physician should be able to confirm or predict this by week 16 of gestation. With our test, we can accurately determine a baby’s gender by the 10th gestational week.
This is a non-invasive, low-risk test, and providing a sample for examination is simple and easy. The results of your test will be available within 10 days.
The technique starts with collecting a maternal blood sample, without affecting the health of the mother or the future babies.
Book an appointment to carry out this noninvasive prenatal test, starting from the 10th gestational week, click below to book your appointment.
Permiso Cofepris: 133300201A1156
Dr. Felipe Camargo Cédula Profesional SEP: 4452501
©Todos los derechos reservados 2024. Instituto Ingenes, Fertilidad & Genética